Entering text into the input field will update the search result below

First GA patient treated with StemCells' HuCNS-SC neural stem cells

Jul. 20, 2015 10:37 AM ETMicrobot Medical Inc. (MBOT) StockMBOTBy: Douglas W. House, SA News Editor7 Comments
  • The first geographic atrophy (GA) patient has been transplanted with StemCells' (STEM +2%) proprietary HuCNS-SC neural stem cells in its Phase 2 clinical trial in dry age-related macular degeneration. GA is the most advanced form of the condition.
  • The primary endpoint of the 63-subject proof-of-concept study, called RADIANT, is the change in GA area as measured by fundus autofluorescence at month 12. The estimated completion date of the trial is December 2017.
  • Age-related macular degeneration is characterized by the loss of photoreceptors (rods and cones) from the central part of the retina (macula). It typically manifests in older people and is the leading cause of severe vision loss and legal blindness in adults over the age of 55.

Recommended For You

About MBOT Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MBOT--
Microbot Medical Inc.